AzurRx BioPharma (NASDAQ: AZRX), a clinical stage biopharmaceutical company specializing in the development of targeted, nonsystemic therapies for gastrointestinal (“GI”) diseases, has shared a letter to shareholders from chair, president and CEO James Sapirstein. The letter noted that AZRX is on track to launch its niclosamide programs in the clinic, noting that just this month the company … Continue reading “NetworkNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Shareholder Letter Outlines Program Highlights, Provides Business Update”
AzurRx BioPharma (NASDAQ: AZRX), a clinical stage biopharmaceutical company specializing in the development of targeted, nonsystemic therapies for gastrointestinal (“GI”) diseases, has entered into an agreement with PPD Inc. (NASDAQ: PPD) for its upcoming phase 1b/2a clinical trial. PPD, a leading global contract research organization will manage the clinical trial using both oral immediate-release tablet and topical rectal enema … Continue reading “NetworkNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Enters Agreement for Upcoming Phase 1b/2a Clinical Trial”
AzurRx BioPharma (NASDAQ: AZRX), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (“GI”) diseases, today announced that it has initiated its Phase 2 RESERVOIR clinical trial of a proprietary oral formulation of micronized niclosamide (“FW-1022”) for the treatment of COVID-19-related gastrointestinal (GI) infections. Patient enrollment is expected to begin … Continue reading “NetworkNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Initiates Phase 2 RESERVOIR Trial for Treatment of COVID-19 GI Infections”
AzurRx BioPharma (NASDAQ: AZRX), a clinical stage biopharmaceutical company specializing in the development of targeted, nonsystemic therapies for gastrointestinal (“GI”) diseases, has shared key takeaways from its topline results on its Phase 2b OPTION 2 clinical trial. The trial studied AzurRx’s drug candidate MS1819 in the treatment of cystic fibrosis (“CF”) patients with exocrine pancreatic insufficiency (“EPI”). … Continue reading “NetworkNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Announces Key Results from Phase 2b OPTION 2 Clinical Trial”
AzurRx BioPharma (NASDAQ: AZRX), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (“GI”) diseases, today announced completion of enrollment in its Phase 2 trial evaluating MS1819 in combination with the current standard of care, porcine-derived pancreatic enzyme replacement therapy (“PERT”). The combination trial is for the treatment of severe … Continue reading “NetworkNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Completes Enrollment in Phase 2 MS1819-PERT Combination Clinical Trial”
AzurRx BioPharma (NASDAQ: AZRX), a clinical-stage biopharmaceutical company specializing in the development of targeted, nonsystemic therapies for gastrointestinal (“GI”) diseases, has announced the completion of enrollment for its phase 2b OPTION 2 clinical trial to investigate MS1819 in cystic fibrosis (“CF”) patients with exocrine pancreatic insufficiency (“EPI”). According to the announcement, the company enrolled 30 … Continue reading “NetworkNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Completes Enrollment in Upcoming Phase 2b Clinical Trial of Cystic Fibrosis Treatment”
AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of nonsystemic, recombinant therapies for gastrointestinal diseases, has announced that its CEO James Sapirstein will present at the virtual Maxim Group Emerging Growth Virtual Conference. The two-day conference is slated for March 17–18, 2021. During the online event, all registered attendees will be able to access Sapirstein’s presentation … Continue reading “NetworkNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Announces Participation in Emerging Growth Virtual Conference”
AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of targeted, non-systemic therapies for gastrointestinal (“GI”) diseases, today announced that its CEO and Chairman, James Sapirstein, will participate in a panel discussion during the ROTH Conference slated to be held virtually from March 15-17, 2021. According to the update, the panel, “Therapeutics Against SARS-CoV-2 – … Continue reading “NetworkNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Announces Plans to Participate in 33rd Annual ROTH Conference, $10M Registered Direct Offering”
AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of targeted, non-systemic therapies for gastrointestinal (“GI”) diseases, today announced that its chairman and CEO, James Sapirstein, will participate in a “fireside chat” with Yi Chen, managing director, Equity Research at H.C. Wainwright, during the H.C. Wainwright Global Life Sciences Conference being held virtually March 9-11, … Continue reading “NetworkNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) to Participate in ‘Fireside Chat’ at Upcoming H.C. Wainwright Conference”
AzurRx BioPharma (NASDAQ: AZRX), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (“GI”) diseases, today announced the appointment of James Sapirstein, president and CEO, as chairman of the company’s board of directors, effective immediately. Sapirstein succeeds Edward J. Borkowski, who joined the AzurRx board in May 2015 and has … Continue reading “NetworkNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Appoints New Chairman of the Board”
